Skip to main content
Premium Trial:

Request an Annual Quote

Almac Diagnostics, Invitrogen, University of Lund

Almac Diagnostics this week launched its Ovarian Disease-Specific Array, a research tool for ovarian cancer studies. The chip includes disease-specific information and is optimized for use with formalin- fixed, paraffin-embedded tissue, Almac said.
According to Almac, the Ovarian DSA contains probe sets representing mitochondrial transcripts, antisense transcripts, alternatively polyadenylated transcripts, and novel transcripts. It offers researchers the ability to reveal the mechanisms and pathways underlying ovarian cancer and to classify and sub-classify the disease and develop diagnostic, prognostic, and predictive signatures, the firm said.   

Invitrogen last week released its ProtoArray Human Protein Microarray Version 4.1.
The latest version of ProtoArray includes over 8,000 proteins, as well as new features including a positional mapping agent for radiolabeled, small-molecule profiling; positive controls for ubiquitination and sumoylation studies; control content for optimized data normalization algorithms for biomarker discovery; and human IgA and anti-human IgA gradients to allow for IgA serum antibody profiling.
Invitrogen also launched its ProtoArray Prospector v5.1 software, which now includes optimized report output and data normalization; new algorithms for analysis of small-molecule profiling data, and an auto-update feature, the company said.

Sweden's University of Lund has released BASE (BioArray Software Environment) 2.8, a free database for microarray data, here.
New features include several batch import/update plug-ins that allow users to import data more easily than prior versions of the software.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.